Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Elbasvir

FDA-approved product (tablet, oral).

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Elbasvir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP10

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis69.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Elbasvir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Elbasvir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)

    NCT02105454 · start 2014-05-23

    Registered record
    Registry ID
    NCT02105454
    Conditions
    Hepatitis C Virus
    Interventions
    Grazoprevir (GZR); Elbasvir (EBR); Ribavirin (RBV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05-23
    Completion
    2015-05-04
    Enrolment
    79

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    InterventionGrazoprevir (GZR); Elbasvir (EBR); Ribavirin (RBV)
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

    NCT02092350 · start 2014-03-17

    Registered record
    Registry ID
    NCT02092350
    Conditions
    Hepatitis C Virus
    Interventions
    Grazoprevir; Elbasvir; Placebo to Grazoprevir; Placebo to Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-03-17
    Completion
    2015-09-02
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    InterventionGrazoprevir; Elbasvir; Placebo to Grazoprevir; Placebo to Elbasvir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)

    NCT01932762 · start 2013-10-01

    Registered record
    Registry ID
    NCT01932762
    Conditions
    Hepatitis C
    Interventions
    Grazoprevir; Elbasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2014-12-04
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionGrazoprevir; Elbasvir; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)

    NCT01937975 · start 2013-09-06

    Registered record
    Registry ID
    NCT01937975
    Conditions
    Chronic Hepatitis C; Renal Impairment
    Interventions
    Grazoprevir; Elbasvir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-09-06
    Completion
    2013-12-17
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Renal Impairment
    InterventionGrazoprevir; Elbasvir
    PhasePhase 1
    Registry statusCompleted

  • An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C

    NCT03423641 · start 2011-01-01

    Registered record
    Registry ID
    NCT03423641
    Conditions
    Hepatitis C, Chronic
    Interventions
    Direct Acting Antivirals
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-01-01
    Completion
    2017-12-31
    Enrolment
    33,808

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionDirect Acting Antivirals
    PhaseNot recorded
    Registry statusCompleted